MCC is current case for SRX, SRX is proven for non-standard malignant tumours at end of lives. BTG would be an interesting competitor as BTG trials would need to be successful & cost of treatment stack up against incumbent treatment IMHO.
Add to My Watchlist
What is My Watchlist?